Home / ETFis Series Trust I / Virtus Biotech Clinical Trials ETF
Virtus Biotech Clinical Trials ETF
A series of ETFis Series Trust I
- Vote records
- 863year to 30 June 2026
- Against management
- 23.2%200 of 863 marked votes
- Say-on-pay support
- 89.0%for, of for + against + abstain
- Shareholder-proposal support
- not reportedfor, of for + against + abstain
Virtus Biotech Clinical Trials ETF is a series of ETFis Series Trust I. For the year to 30 June 2026 its registrant reported 863 vote records for the series; 23.2% of the votes marked for or against management went against management. It voted for 89.0% of say-on-pay items.
Compared with its registrant
| year to 30 June 2026 | This series | Its registrant | Median fund registrant |
|---|---|---|---|
| Against-management share | 23.2% | 9.9% | 6.2% |
| Say-on-pay support rate | 89.0% | 89.8% | 91.6% |
| Shareholder-proposal support rate | not reported | 19.7% | 27.5% |
Votes by category
foragainstabstain, withhold or otheramber tick: the portion cast against management
| Category (as the form names it) | Votes | For | Against | Against management | Split |
|---|---|---|---|---|---|
| DIRECTOR ELECTIONS | 421 | 268 | 20 | 36.3% | |
| SECTION 14A SAY-ON-PAY VOTES | 216 | 166 | 20 | 9.3% | |
| AUDIT-RELATED | 129 | 129 | 0 | 0.0% | |
| SHAREHOLDER RIGHTS AND DEFENSES | 1 | 1 | 0 | 0.0% | |
| EXTRAORDINARY TRANSACTIONS | 6 | 6 | 0 | 0.0% | |
| CAPITAL STRUCTURE | 20 | 14 | 6 | 30.0% | |
| COMPENSATION | 45 | 27 | 18 | 40.0% | |
| CORPORATE GOVERNANCE | 26 | 23 | 3 | 11.5% |
By season
| Season | Vote records | Against management | Say-on-pay support | Shareholder-proposal support |
|---|---|---|---|---|
| year to 30 June 2024 | 707 | 27.2% | 80.0% | not reported |
| year to 30 June 2025 | 966 | 26.3% | 82.0% | not reported |
| year to 30 June 2026 | 863 | 23.2% | 89.0% | not reported |
Questions
How often did Virtus Biotech Clinical Trials ETF vote against management?
23.2% of the votes its registrant marked for or against management in the year to 30 June 2026 (200 of 863).
How did Virtus Biotech Clinical Trials ETF vote on executive pay?
It voted for 162 of 182 say-on-pay items cast for, against or abstain (89.0%).
Is this the result of the meetings?
No. Form N-PX shows how the fund voted the shares it held. It does not show how other shareholders voted or what the outcome was.
Where does the data come from?
From the Form N-PX filed by ETFis Series Trust I, which lists the series that cast each vote. The SEC does not verify the contents. Data runs through 23 Sep 2026.
Provenance: SEC EDGAR, Form N-PX filed by ETFis Series Trust I (filer no. 1559109); votes attributed to series S000047353 by the filer. Not verified by the SEC. Filings read through 23 Sep 2026.